Background. Golgi phosphoprotein 3 (GOLPH3) is associated with worse prognosis of gliomas, but its role and mechanism in glioma progression remain largely unknown. This study aimed to explore the role and mechanism of GOLPH3 in glioma progression. Methods. The expression of GOLPH3 in glioma tissues was detected by quantitative PCR, immunoblotting, and immunohistochemistry. GOLPH3's effect on glioma progression was examined using cell growth assays and an intracranial glioma model. The effect of GOLPH3 on epidermal growth factor receptor (EGFR) stability, endocytosis, and degradation was examined by immunoblotting and immunofluorescence. The activity of Rab5 was checked by glutathione S-transferase pulldown assay. Results. GOLPH3 was upregulated in gliomas, and its downregulation inhibited glioma cell proliferation both in vitro and in vivo. Furthermore, GOLPH3 depletion dampened EGFR signaling by enhancing EGFR endocytosis, driving EGFR into late endosome and promoting lysosome-mediated degradation. Interestingly, GOLPH3 bound to Rab5 and GOLPH3 downregulation promoted the activation of Rab5. In addition, Rab5 depletion abolished the effect of GOLPH3 on EGFR endocytosis and degradation. Conclusion. Our results imply that GOLPH3 promotes glioma cell proliferation via inhibiting Rab5-mediated endocytosis and degradation of EGFR, thereby activating the phosphatidylinositol-3 kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) signaling pathway. We find a new mechanism by which GOLPH3 promotes tumor progression through regulating cell surface receptor trafficking. Extensive and intensive understanding of the role of GOLPH3 in glioma progression may provide an opportunity to develop a novel molecular therapeutic target for gliomas.
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Epidermal growth factor receptor (EGFR) plays an essential role in controlling cell growth. 2, 3 As we know, when ligand is bound to EGFR, the Ras-mitogen-activated protein kinase (MAPK) pathway or phosphatidylinositol-3 kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) signaling will be activated, leading to several gene transcriptions and new protein synthesis responsible for proliferation, migration, adhesion, differentiation, and apoptosis. 2, 4 Thereafter, EGFR and its ligand complex are internalized via receptor-mediated endocytosis to prevent the EGFR signaling overexcitation. 5 After internalization, EGFR traffics through a series of endosomal compartments and is either recycled back to the plasma membrane for reusing or resorted to the lysosome for degradation. 6, 7 Dysregulation of this balance between EGFR activation and internalization will cause abnormal cell growth, leading to tumor formation. However, the regulating mechanism of EGFR internalization, especially in cancer biology, is still unclear.
Golgi phosphoprotein 3 (GOLPH3), also known as GOPP1, GPP34, GMx33, or MIDAS, is a highly conserved protein enriched at the trans-face of golgi cisternae 8, 9 and is implicated in several physiological functions such as golgi architecture maintenance, protein trafficking, receptor recycling and glycosylation, DNA-damageinduced Golgi dispersal and cell survival, and cytokinesis. [10] [11] [12] [13] In 2009, it was first reported that GOLPH3 promotes cell transformation and tumor growth by enhancing activity of the mTOR. 14 Thereafter, GOLPH3 is reported to be upregulated in many types of human tumors, such as esophagus, tongue, breast, and others, and is related with the poor prognosis of tumors. [14] [15] [16] [17] [18] [19] [20] Although GOLPH3 is also upregulated in gliomas and indicated for worse prognosis, 16, 21 its role and mechanism in glioma progression remain largely unknown. In this study, we revealed, for the first time, that GOLPH3 downregulation suppressed glioma cell growth by promoting EGFR endocytosis and degradation, which in turn inhibited PI3K-Akt-mTOR signaling. Furthermore, GOLPH3 depletion promoted internalization of EGFR by interacting and activating Rab5, a protein required for EGFR endocytosis. [22] [23] [24] 
Materials and Methods
Methodological details are provided in the Supplementary material.
Glioma and Nontumorous Brain Tissues
Human primary glioma samples and nontumorous brain tissues (most from the cortex of patients with decompressive surgery after physical injury to the brain) were obtained frozen or paraffin-embedded from the Affiliated Hospital of Xuzhou Medical University. Gliomas were diagnosed by the Department of Pathology according to the 2007 WHO Classification of Tumors of the Central Nervous System. The specimens were collected from the patients registered at the above-mentioned hospital from January 2013 to December 2014, and written informed consent was obtained from the patients. The use of human tissues was approved by the ethics committee of the hospital.
Cell Culture
U251, U87, U118, and A172 cell lines were purchased from the Shanghai Cell Bank, Type Culture Collection Committee, Chinese Academy of Sciences. Cell lines passed the test of DNA profiling (short tandem repeat) and were cultured in Dulbecco's modified Eagle's medium and F-12 (Gibco), supplemented with 10% fetal bovine serum. Sometimes, cells were treated with 100 ng/mL EGF (Invitrogen), 10 μg/mL cycloheximide (Sigma), or 30 μM gefinitib (Selleck) for the indicated time 48 h after transfection.
Small Interfering RNA Transfection and Plasmids
Glioma cells were transiently transfected with small interfering (si)RNAs against human GOLPH3 or Rab5 using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Both GOLPH3 and Rab5 siRNA duplexes were generated by Shanghai Gene Pharma. GOLPH3 siRNA duplexes were designed against a region starting from 571 nucleotide (nt) (siRNA 571), 635 nt (siRNA 635), or 792 nt (siRNA 792). All the transfections were performed 3 times independently.
To establish stable GOLPH3 downregulation of U87 cells, we generated lentivirus-based short hairpin (sh) RNA targeting human GOLPH3 with pLL3.7 as the backbone. Cells were infected with lentivirus containing shGOLPH3 or a control scrambled shRNA (shNC). Flagtagged GOLPH3 was generated from pBABE-HA-GOLPH3 (Addgene, #21687). An shRNA-resistant mutant of GOLPH3 (GOLPH3 Res ) was generated based on the wild type of Flag-tagged GOLPH3 (GOLPH3 WT ) with G replacing A at the 798 nt.
Importance of the study
GOLPH3 is associated with worse prognosis of gliomas, but its role and mechanism in glioma progression remain largely unknown. We found that GOLPH3 was upregulated in gliomas and GOLPH3 depletion inhibited glioma cell growth both in vitro and in vivo. Furthermore, by activating the small GTPase Rab5, GOLPH3 downregulation promoted EGFR endocytosis and degradation, leading to PI3K-Akt-mTOR pathway inhibition and glioma cell growth inhibition. We found a new mechanism by which GOLPH3 promotes tumor progression through regulating cell surface receptor trafficking (eg, EGFR). Extensive and intensive understanding of the role of GOLPH3 in glioma progression may provide an opportunity to develop a novel molecular therapeutic target for gliomas.
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Cell Growth Assays
The cell growth was estimated by Cell Counting Kit-8 (CCK8) assay (Beyotime), cell number counting (Cedex XS), or EdU incorporation assay (RiboBio) according to the manufacturer's instruction. 25 Quantitative PCR and Reverse-Transcription PCR After RNA isolation, cDNA was synthesized using a Firststrand cDNA Kit (Roche) following the manufacturer's instructions. 26 
Immunohistochemistry and Immunoblotting
Immunohistochemistry and immunoblotting were performed according to our previous study. 27 
Coimmunoprecipitation
Protein was incubated with 1 μg of indicated antibodies and Protein A agarose (Roche) at 4°C overnight with rocking. 28 Immunoprecipitation complexes were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for immunoblotting analysis.
Immunofluorescence
Immunofluorescence was performed according to our previous study. 28 
Glutathione S-transferase Pulldown
The Rab5-binding domain of rabaptin-5 glutathione S-transferase (GST)-fusion protein (GST-R5BD) was expressed by pGEX/rabaptin-5, which was a kind gift of Dr Guangpu Li (University of Oklahoma Health Sciences Center), in the Escherichia coli upon isopropyl β-Dthiogalactoside induction and purified with glutathionesepharose 4B resin (Gibco). Cell lysates (500 μg) were incubated with 5 μg of GST-R5BD bound to the glutathionesepharose 4B resin for 2-6 h at 4°C on a rotating mixer. The complex was subjected to 10% SDS-PAGE, and immunoblotted with anti-Rab5 antibody.
Intracranial Glioma Model in Nude Mice
An intracranial model of glioma in nude mice was performed according to our previous study. 29 Briefly, shGOLPH3 or shNC U87 cells (1 × 10 6 ) were injected into the right caudate putamen of athymic nude mice (n ≥ 5 per group). Tumor volume was calculated according to the formula V = 1/2 ab 2 , with "a" representing the longest diameter and "b" representing the shortest diameter. To obtain the survival curve, the mice were sacrificed after they exhibited neurological symptoms. All animal experiments were performed according to the guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee of Xuzhou Medical University.
Statistical Analysis
The results were representative of experiments repeated at least 3 times and presented as mean ± SEM. Statistical comparisons of data from the experiments on cultured cells or mice were performed using Student's t-test with 2 tails or one-way ANOVA for multiple comparisons followed by Dunnett's t-test for post hoc pairwise comparisons. Overall survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. P-values less than 0.05 were considered statistically significant (*P < 0.05, **P < 0.01).
Results and Discussion
GOLPH3 Is Upregulated in Human Glioma Tissues
To elucidate the role and clinical significance of GOLPH3 in gliomas, we first analyzed the database of The Cancer Genome Atlas (https://cancergenome.nih.gov/, Accessed 19 June 2017) and found that gliomas with a high GOLPH3 level exhibited shorter survival time (Fig. 1A ), in line with the report of Zhou et al in patients. 21 Using examination by quantitative PCR, we found that GOLPH3 mRNA levels in GBM significantly increased (Fig. 1B) . Similarly, the protein levels of GOLPH3 in gliomas (grades II, III, and IV) were higher than that of the nontumorous tissues (Fig. 1C, D) . Examined by immunohistochemistry, GOLPH3 positive signals were predominantly located in the cytoplasm and juxtanuclear (Fig. 1E , Supplementary Figure S1 ), and the percentage of GOLPH3-positive cells was significantly higher in gliomas (Fig. 1F ). In addition, the higher the grade of glioma, the higher the level of GOLPH3 (Fig. 1F) . Furthermore, categorized on the basis of positive cell percentage (0, no expression; +, 1%-30%; ++, 31%-65%; +++, >65%), 83.3% (15/18) of nontumorous tissues showed GOLPH3 expression+ and none of the cases showed GOLPH3 expression++. However, in grade II gliomas, there were only 33.3% (3/9) of patients exhibiting GOLPH3 expression+ and about 66.7% (6/9) of cases showing GOLPH3 expression++. In grade IV gliomas, tumors showing GOLPH3 expression++ decreased and those showing GOLPH3 expression+++ increased (Fig. 1G ). These results indicate that GOLPH3 levels were associated with the glioma malignancy, suggesting that GOLPH3 may play an important role in the progression of human gliomas. 
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GOLPH3 Downregulation Inhibits Glioma Progression Both In Vitro and In Vivo
Next, we analyzed the effects of GOLPH3 on glioma cell proliferation by knocking down endogenous GOLPH3 in U251, U87, and U118 cells. As shown in Supplementary Figure S2A and B, 3 sets of siRNA duplexes (si571, si635, and si792) downregulated GOLPH3 by about 60%-80%. Similarly, examined by immunofluorescence, the GOLPH3 level was knocked down dramatically (Supplementary Figure S2C) . In addition, to exclude the possible off-target effect, we generated the stable GOLPH3 downregulation U87 cells (shGOLPH3 cells; Supplementary Figure S3A , B) using lentivirus-based shRNA (based on si792 sequence) and performed the rescue experiment. After transfection of GOLPH3 WT and GOLPH3 Res into shGOLPH3 cells, the GOLPH3 downregulation effect was rescued by GOLPH3 Res but not by GOLPH3 WT (Supplementary Figure S3C) . The above results suggest that the downregulation effect of GOLPH3 si792 is highly efficient and specific, in line with our previous report. 27 Thereafter, examined by EdU incorporation assay, the number of EdU-positive cells was markedly reduced after GOLPH3 downregulation ( Fig. 2A, B , Supplementary Figure S4A , B). Revealed by CCK8 assay, the cell viability was reduced in U251, U87, and U118 cells (Fig. 2C,  Supplementary Figure S4C) . Similarly, the cell number also decreased in 3 cell lines respectively (Supplementary Figure 4D) . In addition, glioma cell growth inhibition induced by GOLPH3 downregulation was rescued by GOLPH3 Res (Supplementary Figure S4E) . Combined with our previous report that GOLPH3 downregulation arrests cells at G0/G1 phase, 30 our results indicate that downregulation of GOLPH3 inhibits glioma cell proliferation in vitro. On the contrary, overexpressing GOLPH3 into A172 glioma cells, which have low GOLPH3 expression (Supplementary Figure S5A) , promoted cell proliferation (Supplementary Figure S5B, C) .
Next, we injected the shGOLPH3 U87 cells into the right caudate putamen of the nude mice to establish an intracranial glioma model. As shown in Fig. 2D , the median survival time of the shGOLPH3 mice was longer than that of the shNC mice. Tumors derived from shGOLPH3 cells were visibly smaller than those from shNC cells (Fig. 2E,  F) . Furthermore, the number of metaphase cells of shNCderived tumors was 1.76-fold more than that of shGOLPH3 cell-derived tumors (Supplementary Figure S6A, B) . Similarly, the Ki67-positive cells of shGOLPH3 cell-derived tumors decreased significantly (Fig. 2G, H) . Together, these results suggest that GOLPH3 is also important for glioma development in vivo.
GOLPH3 Downregulation Decreases the Stability of EGFR and Inhibits Its Downstream Signal
Considering that GOLPH3 promotes cell growth by activating PI3K-Akt-mTOR signaling, 14 which is situated in the downstream of EGFR, we speculated that GOLPH3 might modulate PI3K-Akt-mTOR signaling via regulating EGFR. We thus examined the impact of GOLPH3 on EGFR signaling in glioma cells. Forty-eight hours after GOLPH3 si792 transfection, cells were serum starved for 24 h and treated with cycloheximide for 1 h, followed by EGF treatment for the indicated time. The results showed that GOLPH3 downregulation promoted EGFR degradation after EGF stimulation (Fig. 3A, B) . In addition, the half-life (t 1/2 ) of EGFR significantly decreased after GOLPH3 downregulation (Fig. 3B) .
EGFR activation transduces signaling mainly through the PI3K-Akt or Ras-Raf-extracellular signal-regulated kinase (ERK) pathways. 2 Therefore, we examined the activation of EGFR, Akt, and ERK1/2 in response to EGF treatment after GOLPH3 downregulation. EGFR and Akt phosphorylation markedly decreased in GOLPH3 downregulation cells after EGF treatment, while phospho-ERK1/2 levels showed no difference (Fig. 3C-F) . Importantly, the effect of si792 on EGFR turnover and Akt activation was phenocopied by si635 and rescued by GOLPH3 Res (Fig. 3G, Supplementary  Figure S7A) . Similarly, the effect of si792 on p-EGFR and p-ERK was also phenocopied by si635 (Supplementary Figure S7B-D) . These results exhibit that GOLPH3 downregulation inhibits the PI3K-Akt pathway, but not the ERK1/2 signaling pathway, which is consistent with the previous report. 14 Consistently, overexpression of GOLPH3 increased the EGFR protein level, but not the mRNA level (Supplementary Figure S8A, Figure S8C) , indicating that there is no feedback loop between EGFR and GOLPH3. Next, to explore the possible correlation between GOLPH3 and EGFR, we detected the protein levels of GOLPH3 and EGFR in the same glioma samples at the same time. We found that with the increase of glioma grade, the levels of EGFR increased, similar to the expression pattern of GOLPH3. In addition, the levels of these 2 proteins showed direct correlation to each other (r = 0.899; Fig. 3H, I, Supplementary Figure S9A) . However, using examination by both western blotting and immunohistochemistry, we did not find any association of GOLPH3 with EGFR variant III, the main form of EGFR mutation in GBM (Supplementary Figure S9A, B) .
B). In addition, EGFR overexpression did not affect the GOLPH3 level (Supplementary
Scott et al reported that GOLPH3 activates mTOR signaling, and tumors with a high GOLPH3 level are more sensitive to rapamycin treatment, 14 indicating that GOLPH3 levels may be a positive predictor of rapamycin sensitivity. Therefore, we wonder whether tumors with a high GOLPH3 level show higher sensitivity to the EGFR inhibitor gefitinib. As shown in Supplementary Figure S10 , GOLPH3 overexpression cells have higher responsiveness to gefitinib, indicating that gefitinib could benefit tumors with a high GOLPH3 level.
GOLPH3 Downregulation Enhances EGFR Endocytosis and Degradation
The internalization and lysosomal-mediated degradation of EGFR is an important negative feedback mechanism to regulate the amplitude and kinetics of EGFR signaling. 31, 32 Failure of EGFR endocytosis will enhance receptor signaling, which may lead to cell transformation and tumorigenesis. 33, 34 To investigate whether GOLPH3 affects EGFR endocytosis, we examined the subcellular location of EGFR after GOLPH3 Fig. 4A , before EGF treatment, the EGFR is located at the cell membrane (Fig. 4A top  panel) . However, after EGF treatment for 5 min, the EGFR aggregated at the perinuclear region and the EGFR at the cell surface significantly decreased (Fig. 4A bottom panel) . Interestingly, the level of EGFR at the perinuclear region increased after GOLPH3 downregulation (Fig. 4A lower  right) , suggesting that GOLPH3 downregulation might promote EGFR endocytosis. In addition, the effect of si792 on EGFR endocytosis was phenocopied by si635 and rescued by GOLPH3 Res (Fig. 4B, Supplementary Figure S11) .
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downregulation. As shown in
Next, we examined whether GOLPH3 regulates EGFR trafficking through endo-lysosomal compartments. First, we found that the endogenous GOLPH3 was basally colocalized with EGFR in vesicle-like structures and the co-localization rate dramatically increased after EGF stimulation (Fig. 4C, Supplementary Figure S12A ). In addition, GOLPH3 was partially co-localized with EEA1, an early endosomal marker (Supplementary Figure S12B) , in line with the previous study. 35 As expected, the co-localization rate of EGFR with EEA1 increased in GOLPH3-depleted cells after EGF treatment for 5 min (Fig. 4D, E) . Similarly, GOLPH3 depletion also enhanced the co-localization of EGFR with late endosomal marker M6PR and the lysosomal marker LAMP1 after EGF treatment for 15 min (Fig. 4F, G) or 30 min (Fig. 4H, I ), respectively. These results indicate that depletion of GOLPH3 promotes EGFR endocytosis and rapid lysosome-mediated degradation.
GOLPH3 Binds to and Inhibits the Activation of Rab5
Activation of Rab5, a small GTPase, is required for both internalization and trafficking of EGFR to endosomal compartments, leading to EGFR degradation. [22] [23] [24] EGFR activation causes conversion of Rab5 from the GDP-bound inactive form into the GTP-bound active form, thereby stimulating trafficking of the receptor along the early endocytic pathway. 36 Therefore, we examined the possibility that GOLPH3 affects the endocytosis and degradation of EGFR by regulating Rab5. First, we found that the endogenous GOLPH3 co-precipitated with endogenous Rab5 and EGFR without EGF treatment (Fig. 5A) . Interestingly, the GOLPH3/ EGFR/Rab5 complex increased after EGF treatment for 15 min (Fig. 5A) . Similarly, GOLPH3, EGFR, and Rab5 colocalized with each other both before and after EGF stimulation (Fig. 5B) .
After being activated by the Rab5 guanine exchange factor (GEF) rabex 5, Rab5 recruits its effector rabaptin-5 to early endosomes and exhibits effect on receptor endocytosis. 37, 38 Thus, taking advantage of the Rab5-binding domain of the GST-R5BD fusion protein pulldown assay, a classic method to detect the activity of Rab5 (GTP-Rab5), we test the effect of GOLPH3 on Rab5 activity. As shown in Fig. 5C , D, GTP-Rab5 increased after downregulation of GOLPH3 without EGF treatment. After EGF stimulation for 5 min, GTP-Rab5 increased by about 2-fold in GOLPH3-depleted (Fig. 5C, D) . In addition, the effect of si792 on Rab5 activation was rescued by GOLPH3 Res and phenocopied by si635 (Fig. 5E, Supplementary Figure S13A) . Furthermore, the increase of Rab5 clusters or co-localization with EGFR after GOLPH3 downregulation was rescued by GOLPH3 Res and phenocopied by si635 (Fig. 5F, Supplementary Figure  S13B ), indicating that GOLPH3 may function through Rab5 in EGF-dependent and -independent manners.
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Rab5 Is Critical for GOLPH3-Mediated EGFR Endocytosis and Degradation
Next, we examined whether Rab5 is required for GOLPH3-mediated EGFR endocytosis. To inhibit Rab5 activation, we downregulated Rab5 with siRNA and found that the Rab5 level decreased by about 60% (Supplementary Figure S14A) . After transfection of siGOLPH3 into cells (Supplementary Figure S14B) , with or without siRab5, the endocytosis of EGFR increased in GOLPH3 downregulation cells (Fig. 6A upper middle and Fig. 6B ), in line with our previous result (Fig. 4A) . In addition, the EGFR endocytosis induced by GOLPH3 downregulation was eliminated by Rab5 depletion (Fig. 6A, upper right, Fig. 6B ). Furthermore, immunostained with anti-EGFR antibody without permeabilization (to visualize the surface EGFR only), the surface level of EGFR significantly decreased after EGF treatment for 5 min in GOLPH3-depleted cells (Fig. 6A, bottom middle, Fig. 6C ). Consistently, the decreased surface level of EGFR induced by GOLPH3 downregulation was abolished by siRab5 (Fig. 6A, bottom right, Fig. 6C ). In addition, the above results were rescued by GOLPH3 Res (Supplementary Figure S15A) and phenocopied by si635 (Supplementary Figure S15B) . Furthermore, knockdown of Rab5 abolished EGFR into early and late endosomes induced by GOLPH3 downregulation (Fig. 6D, E, Supplementary Figure S16A , B). The above findings indicate that Rab5 is critical for GOLPH3 downregulation induced EGFR endocytosis and trafficking to early and late endosomes.
Based on the above results, a possible model is depicted in Fig. 6F . Upon EGF stimulation (left), a high level of GOLPH3 in gliomas is recruited to inhibit Rab5 activation and EGFR endocytosis/degradation, which activates its downstream signaling, such as PI3K-Akt-mTOR, to promote cell growth. After GOLPH3 downregulation (right), GOLPH3 cannot be recruited and Rab5 was activated to promote EGFR endocytosis and degradation upon EGF stimulation. Consequently, PI3K-Akt-mTOR signaling was inhibited, leading to glioma progression inhibition.
The previous study reported that GOLPH3 promotes cell growth in breast cancer by suppressing the Forkhead box protein O1 transcription factor. 17 Another paper from the same group reported that GOLPH3 promotes hepatocellular carcinoma cell aggressiveness by activating the nuclear factor-kappaB pathway. 39 In this study, we found that GOLPH3 is upregulated in gliomas and negatively associated with glioma survival. In addition, located at early endosomes, GOLPH3 inhibits the endocytosis and degradation of EGFR by inhibiting Rab5 activation and thus activates PI3K-Akt signaling, which in turn promotes glioma cell growth.
Our study reported, for the first time, that GOLPH3 downregulation decreases the stability and activation of EGFR and enhances its endocytosis and degradation after EGF stimulation. Notably, GOLPH3 depletion promotes EGFR endocytosis and degradation, which in turn inhibited the PI3K-Akt-mTOR but not the Ras-Raf-ERK signaling pathway. As for why phosphorylation of ERK persists with knockdown of GOLPH3 despite the apparent loss of signaling by the EGFR, one possible explanation so far is that although GOLPH3 downregulation promotes the endocytosis and degradation of EGFR, EGF signaling is not totally blocked (Fig. 3B) . In addition, there may exist other different mechanisms for phosphorylation of ERK after EGFR signaling inhibition induced by GOLPH3 depletion. For example, it is reported that, apart from EGFR, the MAPK/ ERK pathway can be activated through other cell surface receptors, such as G-protein couple receptor [GPCR]). 40 Rab5 activation was required for both internalization and trafficking of EGFR to endosomal compartments. In addition to regulating endosomal trafficking of EGFR, Rab5 is involved in recycling of other receptors, such as GPCRs and angiotensin II type 1A receptor. 41, 42 Rab5 activation is, at least in part, mediated by Rab5 GEF RIN1, which is activated by the small GTPase Ras after EGF receptor stimulation. 43 However, both the function and the regulation of Rab proteins in cancer development are poorly understood. In the present study, we found that GOLPH3 binds to Rab5 and inhibits Rab5 activation, indicating that GOLPH3 can regulate Rab5 activity. Does GOLPH3 bind to Rab5 directly? How does GOLPH3 regulate the activity of Rab5? Does GOLPH3 regulate Rab5 activity through Rab5 GEF RIN1? What is the role of Rab5 in cancer development? All of these questions deserve further study. Fig. 6 Rab5 is critical for GOLPH3-mediated EGFR endocytosis and degradation. (A) The endocytosis of EGFR induced by knockdown of GOLPH3 with si792 was interrupted by siRab5. Cells were treated with EGF for 5 min, stained with EGFR (white) and DAPI (blue) with (top) or without (bottom) permeabilization to visualize total EGFR or surface EGFR only. (B, C) Quantitative results of (A). *P < 0.05; **P < 0.01. (D, E) After EGF treatment, the recruitment of EGFR to early endosomes (D) or late endosomes (E) induced by knocking down of GOLPH3 was eliminated by siRab5. Scale bar: 20 μm. (F) Working model. Upon EGF stimulation, a high level of GOLPH3 in gliomas is recruited to inhibit Rab5 activation and EGFR endocytosis/degradation, which activates its downstream signaling, such as PI3K-Akt-mTOR, to promote cell growth (left). After GOLPH3 downregulation, GOLPH3 cannot be recruited and Rab5 was activated to promote EGFR endocytosis and degradation upon EGF stimulation. Consequently, EGFR endocytosis and degradation inhibited PI3K-Akt-mTOR signaling to inhibit glioma progression (right).
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In addition, we found that cells with high levels of GOLPH3 showed higher sensitivity to EGFR inhibitor gefitinib treatment, indicating that gefitinib could benefit tumors with high GOLPH3 levels. Is the GOLPH3 level a positive predictor of gefitinib sensitivity? It will be interesting to examine this hypothesis extensively in primary glioma cells, mice, and even in patients. Collectively, extensive and intensive understanding of the role of GOLPH3 in glioma progression may provide an opportunity to develop a novel molecular therapeutic target for gliomas.
Supplementary material
Supplementary material is available at Neuro-Oncology online.
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